Free Trial

International Biotechnology (IBT) Competitors

International Biotechnology logo
GBX 658 +2.00 (+0.30%)
As of 11:58 AM Eastern

IBT vs. OCI, RICA, SAIN, CGT, ICGT, IEM, JEO, MUT, APEO, and NBPE

Should you be buying International Biotechnology stock or one of its competitors? The main competitors of International Biotechnology include Oakley Capital Investments (OCI), Ruffer Investment (RICA), Scottish American Investment (SAIN), Capital Gearing (CGT), ICG Enterprise Trust (ICGT), Impax Environmental Markets (IEM), European Opportunities Trust (JEO), Murray Income Trust (MUT), abrdn Private Equity Opportunities (APEO), and NB Private Equity Partners (NBPE). These companies are all part of the "asset management" industry.

International Biotechnology vs. Its Competitors

Oakley Capital Investments (LON:OCI) and International Biotechnology (LON:IBT) are both small-cap asset management industry companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

International Biotechnology has a net margin of 90.66% compared to Oakley Capital Investments' net margin of 88.84%. International Biotechnology's return on equity of 13.67% beat Oakley Capital Investments' return on equity.

Company Net Margins Return on Equity Return on Assets
Oakley Capital Investments88.84% 7.17% 4.33%
International Biotechnology 90.66%13.67%3.57%

Oakley Capital Investments has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, International Biotechnology has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500.

Oakley Capital Investments pays an annual dividend of GBX 5 per share and has a dividend yield of 1.0%. International Biotechnology pays an annual dividend of GBX 29 per share and has a dividend yield of 4.4%. Oakley Capital Investments pays out 10.0% of its earnings in the form of a dividend. International Biotechnology pays out 27.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Oakley Capital Investments has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Oakley Capital Investments, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oakley Capital Investments£99.08M9.29£88.03M£49.9010.46
International Biotechnology£41.82M5.65£37.91M£104.806.28

In the previous week, Oakley Capital Investments' average media sentiment score of 0.00 equaled International Biotechnology'saverage media sentiment score.

Company Overall Sentiment
Oakley Capital Investments Neutral
International Biotechnology Neutral

50.2% of Oakley Capital Investments shares are owned by institutional investors. Comparatively, 45.2% of International Biotechnology shares are owned by institutional investors. 20.9% of Oakley Capital Investments shares are owned by insiders. Comparatively, 4.2% of International Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Oakley Capital Investments beats International Biotechnology on 9 of the 13 factors compared between the two stocks.

Get International Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IBT vs. The Competition

MetricInternational BiotechnologyAsset Management IndustryFinancial SectorLON Exchange
Market Cap£236.36M£1.30B£6.35B£3.02B
Dividend Yield4.20%4.40%4.20%5.02%
P/E Ratio6.2822.2914.03165.88
Price / Sales5.652,351.921,730.14285,131.44
Price / Cash155.7460.71128.5127.97
Price / Book0.861.231.964.46
Net Income£37.91M£263.65M£1.24B£5.90B
7 Day Performance4.11%0.22%0.80%3.82%
1 Month Performance9.67%2.81%4.08%9.81%
1 Year Performance-5.73%5.94%19.68%74.29%

International Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IBT
International Biotechnology
N/AGBX 658
+0.3%
N/A-6.3%£236.36M£41.82M6.28N/A
OCI
Oakley Capital Investments
N/AGBX 520
-0.6%
N/A+2.0%£917.34M£99.08M10.42N/A
RICA
Ruffer Investment
N/AGBX 283.50
+0.2%
N/A+4.4%£912.23M£16.91M103.12N/A
SAIN
Scottish American Investment
N/AGBX 513
-0.4%
N/A-0.1%£897.02M£75.38M10.29N/A
CGT
Capital Gearing
N/AGBX 4,810
+0.1%
N/A+2.4%£894.54M£17.92M19.56N/A
ICGT
ICG Enterprise Trust
N/AGBX 1,380
-0.7%
N/A+7.1%£891.87M£55.63M27.56N/A
IEM
Impax Environmental Markets
N/AGBX 383
-1.0%
N/A-0.8%£889.13M£1.35M-95.27N/APositive News
JEO
European Opportunities Trust
N/AN/AN/AN/A£886.70M-£62.33M-12.93N/A
MUT
Murray Income Trust
N/AGBX 886.50
+0.2%
N/A+1.4%£885.69M£97.96M9.77147,000Dividend Cut
High Trading Volume
APEO
abrdn Private Equity Opportunities
N/AN/AN/AN/A£880.29M£80.21M1,435.00N/A
NBPE
NB Private Equity Partners
N/AGBX 1,484
-0.4%
N/A-12.0%£860.73M£12.90M-38.92N/A

Related Companies and Tools


This page (LON:IBT) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners